A Phase IIb, Multi-Centre, Randomised, Double-Blind, Active-Controlled Trial Comparing the Neuropsychiatric Adverse Event Profile of Etravirine 400mg qd Versus Efavirenz 600mg qd in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in ARV Therapy-naive HIV-1 Infected Subjects.

Trial Profile

A Phase IIb, Multi-Centre, Randomised, Double-Blind, Active-Controlled Trial Comparing the Neuropsychiatric Adverse Event Profile of Etravirine 400mg qd Versus Efavirenz 600mg qd in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in ARV Therapy-naive HIV-1 Infected Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2013

At a glance

  • Drugs Efavirenz (Primary) ; Etravirine (Primary) ; Nucleoside reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms SENSE
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2012 Company added in association field as reported by European Clinical Trials Database.
    • 29 Dec 2011 Results assessing the effects of treatment on serum lipids published in the Journal of Antimicrobial Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top